- Home
- XFOR vs AVTX Comparison
XFOR vs AVTX Comparison
Compare XFOR & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XFOR | AVTX |
|---|---|---|
| Founded | 2014 | 2011 |
| Country | United States | United States |
| Employees | 143 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 407.5M | 328.4M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | XFOR | AVTX |
|---|---|---|
| Price | $4.35 | $15.87 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | $9.00 | ★ $40.57 |
| AVG Volume (30 Days) | 304.0K | ★ 2.4M |
| Earning Date | 05-04-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 72.07 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $27,813,137.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 2312.27 |
| 52 Week Low | $1.35 | $3.93 |
| 52 Week High | $4.83 | $24.27 |
Technical Indicators
Market Signals| Indicator | XFOR | AVTX |
|---|---|---|
| Relative Strength Index (RSI) | 57.03 | 46.43 |
| Support Level | $3.44 | $15.33 |
| Resistance Level | $4.57 | $16.02 |
| Average True Range (ATR) | 0.24 | 1.26 |
| MACD | 0.02 | -0.36 |
| Stochastic Oscillator | 72.12 | 10.30 |
Price Performance
Historical ComparisonAbout XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.